AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00639912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: 154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
Study NCT00639912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate
Description: 154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
Study NCT02562495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT Scan and ultrasonography
Description: Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
Study NCT04581889 — intervention group
Intervention type: OTHER
Intervention: Diagnostic test
Description: Presence of antibodies in saliva
Study NCT04012138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
Study NCT04012138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.
Study NCT04012138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.
Study NCT00837551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WBI-1001
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
Study NCT00837551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WBI-1001
Description: Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
Study NCT02558686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
Study NCT02558686 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Detuned Ultrasound
Description: Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
Study NCT02558686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals will not perform any action after the application of trigger point dry needling
Study NCT00938470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT00938470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00938470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00938470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT00938470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00938470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT00938470 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00938470 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00938470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT00938470 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgery
Study NCT04162340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4 CAR T cells
Description: CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
Study NCT01095263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS
Description: 130Hz, 90us pulsewidth, 4V Amplitude
Study NCT01095263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Stimulation (Sham)
Description: 130Hz, 90us pulsewidth, 0V Amplitude
Study NCT03607539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
Study NCT03607539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.
Study NCT03607539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500mg/m\^2; Q3W (qualer 3 weeks), day1, I.V.
Study NCT03607539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
Study NCT03607539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Platinum
Description: Q3W (qualer 3 weeks), day1, I.V.; first 4 cycles.
Study NCT03607539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 10 mL:100 mg，200mg，Q3W (qualer 3 weeks), day1, I.V.
Study NCT03641612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one shape
Description: canal fluid sample before and after root canal instrumentation
Study NCT03641612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: protaper next
Description: canal fluid sample before and after root canal instrumentation
Study NCT00582868 — intervention group
Intervention type: DEVICE
Intervention: Licox Brain Oxygen Monitor
Description: use of data from brain oxygen monitor for analysis
Study NCT00582868 — intervention group
Intervention type: OTHER
Intervention: CSF
Description: analysis of CSF for cleaved tau protein
Study NCT00582868 — intervention group
Intervention type: OTHER
Intervention: Whole blood
Description: Analysis of whole blood for cleaved-tau protein
Study NCT04119258 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive-behavioral therapy including both behavioral and cognitive interventions.
Study NCT00675090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK239512
Description: GSK239512 oral tablets once a day
Study NCT00675090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match once a day
Study NCT04953715 — intervention group
Intervention type: OTHER
Intervention: collection of body microbioma
Description: A prospective, observational microbiome study of adult kidney transplant recipients receiving mycophenolate mofetil and tacrolimus maintenance immunosuppression. Participants will be studied post-transplant for mycophenolate pharmacokinetics and microbiome samples collected. Clinically measured tacrolimus trough concentrations will also be evaluated. Associations among mycophenolic acid enterohepatic recycling and metabolite formation, tacrolimus troughs, immunosuppression adverse effects, diarrhea and microbiome will be studied.
Study NCT01703351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: (n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
Study NCT01703351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl 500mcg + acupan 160mg + nasea 0.6mg
Description: (n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
Study NCT00599885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telmisartan
Description: telmisartan 40-80mg once per day for 8 months
Study NCT00599885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan
Description: valsartan 80-160mg once per day for 8 months
Study NCT00884494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin infusion to assess effects on insulin sensitivity
Study NCT01122251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lercanidipine + Valsartan
Description: L10/V80, L20/V80, L10/V160, L20/V160
Study NCT01122251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lercanidipine or Valsartan
Description: L10, L20, V80, V160
Study NCT01122251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Lercanidipine and Valsartan
Study NCT01284686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subthalamo-cortical loops stimulation in a one-sided and bipolar way
Description: Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
Study NCT02546518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moniri Otovent
Description: Please see Arm Description.
Study NCT02546518 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tube in the ear drum
Description: Insertion of tympanostomy tube/Grommet in the ear drums.
Study NCT00565188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate
Description: Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
Study NCT02784756 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Quantiferon-CMV assay
Study NCT01284686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subthalamo-cortical loops stimulation in a one-sided and bipolar way
Description: Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
Study NCT01264822 — intervention group
Intervention type: DRUG
Intervention: Rabeprazole Sodium
Description: The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg.
Study NCT05933408 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TREM-1
Description: The TREM-1 (triggering receptor expressed on myeloid cells-1) glycoprotein is a receptor involved in the activation of monocytes and neutrophils during the inflammatory process. There are many reports indicating the soluble form of this receptor is a reliable diagnostic marker of infection and inflammatory response induced by trauma. Therefore the investigators aimed to investigate the potential use of soluble TREM-1 to predict serious infectious complications in patients undergoing laparoscopic colorectal surgery.Blood samples were drawn four times: on the day of surgery (preoperatively) and on the three following postoperative days (PODs).
Study NCT03848728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SEARCH Youth combination intervention
Description: * Administration of life-stage assessment tool~* Structured choice clinic access~* Rapid feedback of VL results~* Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information
Study NCT00114413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Description: Used for both regular asthma control and as a rescue inhaler
Study NCT00114413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteroids
Description: Used for both regular asthma control and as a rescue inhaler
Study NCT00114413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eNO measurement
Description: measured by Aerocrine® NIOX device
Study NCT02170792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Description: Low, medium or high dose
Study NCT02170792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: 150mg
Study NCT02414737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitrophin alfa
Description: use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
Study NCT01749904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
Study NCT01749904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
Study NCT01749904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303259-X
Description: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
Study NCT01749904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOL-303259-X
Description: All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
Study NCT00581815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton-decoupled 31P MRS at 1.5T
Description: The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
Study NCT00581815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1H Spectroscopy at 1.5T and 3T
Description: The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
Study NCT00014131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Vaccine: therapeutic autologous dendritic cells.
Description: Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
Study NCT01306097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: 10mg daily for under 1 years old children and 20mg daily for above 1 years old children
Study NCT00379743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health coordinator (or patient navigator)
Description: Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
Study NCT00379743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational materials only
Description: A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
Study NCT05316194 — intervention group
Intervention type: OTHER
Intervention: Digital treatment for hip and knee osteoarthritis
Description: The program is an app-based version of the Swedish face-to-face management program for OA Better management of patients with OsteoArthrits and includes weekly educational sessions, individualized exercises and a possibility to chat asynchronously with a physical therapist during the entire duration of the program.
Study NCT04385420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-002 MEK Inhibitor
Description: Drug ATR-002 administered as film-coated tablet via oral route
Study NCT04385420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo film-coated tablet administered via oral route
Study NCT01137968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imetelstat
Description: 9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
Study NCT01137968 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
Study NCT01137968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
Study NCT02289612 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yellow Mustard Gum Fibre
Study NCT02289612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Mustard Gum Fibre
Study NCT02289612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Flaxseed Gum Fibre
Study NCT02289612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fenugreek Gum Fibre
Study NCT04388241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Balance Program
Description: The Balance Program is a four-week behavioral intervention (each session lasting 60 minutes) developed specifically for the pediatric SCD population based on existing evidence-based treatments to target the unique presentation of pain-related disability in SCD.
Study NCT03215810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating Lymphocytes (TIL)
Description: Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
Study NCT03215810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
Study NCT03215810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
Study NCT03215810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m\^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
Study NCT03215810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating Lymphocyte Therapy
Description: On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
Study NCT03215810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL2)
Description: Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
Study NCT02931071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: G-CSF (12 μg/Kg/12 h) 8 days.
Study NCT02931071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor